Evidence map›Paper›PMID 26100400›Full record

ArticleBMC cancer2015

A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil.

Jessica L Castilho, José Eduardo Levi, Paula M Luz, Mary Catherine Cambou, Tazio Vanni, Angela de Andrade, Mônica Derrico, Valdiléa G Veloso, Beatriz Grinsztejn, Ruth K Friedman

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Jessica L CastilhoDivision of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, USA. jessica.castilho@vanderbilt.edu.
José Eduardo LeviVirology Lab, Instituto de Medicina Tropical da Universidade de São Paulo, São Paulo, Brazil. dudilevi@usp.br.
Paula M LuzInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. luzpaulamendes@gmail.com.
Mary Catherine CambouDivision of Infectious Diseases and Program in Global Health, David Geffen School of Medicine at UCLA, Los Angeles, USA. mcambou@mednet.ucla.edu.
Tazio VanniDepartamento de Ciência e Tecnologia, Ministério da Saúde, Brasília, Brazil. vannit@fellows.iarc.fr.
Angela de AndradeInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. angela.andrade@ipec.fiocruz.br.
Mônica DerricoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. monica.derrico@gmail.com.
Valdiléa G VelosoInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. valdilea.veloso@gmail.com.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. beatriz.grinsztejn@gmail.com.
Ruth K FriedmanInstituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. ruthkf@gmail.com.
Fundação Oswaldo Cruz · BRInstituto Evandro Chagas · BRDepartamento de Ciência e Tecnologia · BRUniversidade de São Paulo · BRVanderbilt University · US

Funding

CCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Vanderbilt Infection Pathogenesis and Epidemiology Research Training ProgramT32AI007474 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KALAMS, SPYROS A · 1995 to 2025
$6.9M
South American Program in HIV Prevention Research (SAPHIR)R25MH087222 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Karin Nielsen · 2011 to 2026
$3.9M
Mentoring in HIV and Tuberculosis ResearchK24AI065298 · NIAID · VANDERBILT UNIVERSITY · PI STERLING, TIMOTHY R · 2005 to 2014
$1.6M
NIAID NIH HHS K24 AI065298NIAID NIH HHS K24 AI65298NIAID NIH HHS T32 AI007474NIAID NIH HHS U01 AI069923NIAID NIH HHS UM1 AI069476NIAID NIH HHS UO1AI069923NIMH NIH HHS R25 MH087222
6 · The paper itself

Abstract

backgroundIn Brazil, the rate of cervical cancer remains high despite the availability of screening programs. With ongoing vaccine development and implementation, information on the prevalence of specific HPV types is needed, particularly among high-risk populations, such as HIV-infected women.

methodsWe performed a study of HIV-infected women in Rio de Janeiro, Brazil, who underwent cervical HPV genotype testing between 2005-2013. We examined the prevalence of high-risk HPV types and the patterns of high-risk HPV type clustering. Using logarithmic binomial regression, we estimated the risk of abnormal cytology by HPV genotype result.

resultsOf the 562 women included, 498 (89 %) had at least one HPV type detected. 364 women (65 %) had at least one high-risk HPV type detected and 181 (32 %) had more than one high-risk type detected. HPV 58 was the most frequent HPV type detected overall (prevalence 19.8 % [95 % confidence interval 16.4-23.1]), followed by HPV 53 (prevalence 15.5 % [12.5-18.5]) and HPV 16 (prevalence 13 % [10.2-15.8]). Women infected with more than one high-risk HPV type were younger, had lower CD4+ lymphocyte counts, and were more likely to be infected with HPV 16 or 18. In adjusted analyses, presence of more than one high-risk HPV type was associated with a two-fold increased risk of abnormal cytology after adjusting for presence of individual high-risk type, age, and CD4+ lymphocyte count (adjusted prevalence ratios 1.88-2.07, all p <0.001). No single high-risk HPV type was statistically associated with abnormal cytology after adjusting for the presence of more than one high-risk HPV type.

conclusionsIn the largest study of cervical HPV genotypes among HIV-infected women in Latin America, infection by high-risk HPV types other than 16 or 18 and infection by more than one high-risk HPV types were common. Infection by more than one high-risk type was more strongly associated with abnormal cervical cytology than any individual high-risk HPV type, highlighting the need for multi-valent HPV vaccines.

Indexed as

AdultBrazilCross-Sectional StudiesFemaleHIV InfectionsHumansMiddle AgedPapillomaviridaePapillomavirus InfectionsUterine Cervical Neoplasms

Identifiers

PMID26100400
PMCPMC4477502
OpenAlexW2133970414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.